Document detail
ID

doi:10.1007/s12035-021-02686-2...

Author
Abdelhamid, Rehab F. Ogawa, Kotaro Beck, Goichi Ikenaka, Kensuke Takeuchi, Eriko Yasumizu, Yoshiaki Jinno, Jyunki Kimura, Yasuyoshi Baba, Kousuke Nagai, Yoshitaka Okada, Yukinori Saito, Yuko Murayama, Shigeo Mochizuki, Hideki Nagano, Seiichi
Langue
en
Editor

Springer

Category

Biomedicine

Year

2022

listing date

2/10/2022

Keywords
amyotrophic lateral sclerosis mirna pirna piwi protein tdp-43 protein piwil1 rna als
Metrics

Abstract

The pathological hallmark of the majority of amyotrophic lateral sclerosis (ALS) cases is the mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43), an RNA-binding protein.

Several studies have attributed disease processes of ALS to abnormal RNA metabolism.

However, dysregulated biogenesis of RNA, especially non-coding RNA (ncRNA), is poorly understood.

To resolve it, RNA-Seq, biochemical, and immunohistochemical analyses were performed on the pyramidal tract of the medulla oblongata of sporadic ALS (sALS) and control postmortem brain samples.

Here, we report perturbation of ncRNA biogenesis in PIWI-interacting RNA (piRNA) in several sALS brain samples associated with TDP-43 pathology.

In addition, we confirmed the dysregulation of two PIWI homologs, PIWI-like-mediated gene silencing 1 (PIWIL1) and PIWIL4, which bind to piRNAs to regulate their expression.

PIWIL1 was mislocalized and co-localized with TDP-43 in motor neurons of sporadic ALS lumbar cords.

Our results imply that dysregulation of piRNA, PIWIL1, and PIWIL4 is linked to pathogenesis of ALS.

Based on these results, piRNAs and PIWI proteins are potential diagnostic biomarkers and therapeutic targets of ALS.

Abdelhamid, Rehab F.,Ogawa, Kotaro,Beck, Goichi,Ikenaka, Kensuke,Takeuchi, Eriko,Yasumizu, Yoshiaki,Jinno, Jyunki,Kimura, Yasuyoshi,Baba, Kousuke,Nagai, Yoshitaka,Okada, Yukinori,Saito, Yuko,Murayama, Shigeo,Mochizuki, Hideki,Nagano, Seiichi, 2022, piRNA/PIWI Protein Complex as a Potential Biomarker in Sporadic Amyotrophic Lateral Sclerosis, Springer

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw